Jan 2023 Update: BioGX in silico analysis of SARS-CoV-2 Variants of Concern

BioGX continuously monitors the evolution of COVID-19 variants to ensure our market leading SARS-CoV-2 RT-PCR tests will continue to detect emerging variants without impacting performance.


BioGX has completed in-silico analysis of over 930,000 SARS-CoV-2 genome sequences available as of December, 2022. Sequence analysis compared the available Omicron genomes against the SARS-CoV-2 nucleocapsid (N-gene), membrane (M-gene), and RdRp coding region of the ORF1a gene (RdRp) targeted by BioGX products. In-silico analysis and empirical testing of the Omicron variants confirmed gene mutations present as of this analysis, will not affect the performance of the BioGX portfolio of SARS-CoV-2 products.


BioGX portfolio of SARS-CoV-2 products

  1. BioGX Xfree™ COVID-19 Direct RT-PCR – FDA EUA
  2. BioGX SARS-CoV-2 HMP – N1, N2 & RNase P Multiplex
  3. BioGX COVID-19, Flu A, Flu B, RSV RT-PCR for BD MAX™
  4. BioGX SARS-CoV-2 N1, Flu A, Flu B, RSV A/B (RUO)


U.S. CDC and WHO Variants of Concern Omicron Lineages* 

WHO designationPango lineageGISAID
Nextstrain cladeEmergence Location (Date)No. Sequences Analyzed 

(DEC 2022)

% Clades Detected for

N1 Target

OmicronB.1.1.529GR/484A21K, 21L, 21M, 22A, 22B, 22C, 22DMultiple Countries (NOV 2021)61,891> 99%

Omicron Sublineages Analyzed by BioGX

Omicron sublineageNextstrain cladeEmergence Location (Date)No. Sequences Analyzed 

(DEC 2022)

BA.1*21KSouthern Africa (NOV 2021)1,716
BA.1.1*21KSouthern Africa (NOV 2021)3,812
BA.2*21LSouthern Africa (NOV 2021)5,853
BA.3*21KSouthern Africa (NOV 2021)0
BA.4*22ASouthern Africa (JAN 2022)457
BA.5*22BSouthern Africa (JAN 2022)1,888
XE*N/AUK (FEB 2022)0
BQ.1**22ENigeria (JUL 2022)11,841
BQ.1.1**22B Nigeria (JUL 2022)35,142
XBB**22FMultiple Countries (SEP 2022)1,120

*Variants of concern being monitored by US CDC and WHO. 

**Variants not included in CDC or WHO variant of concern list